Algernon Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is September - August.

Millions CAD. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Nov '24 Nov 30, 2024	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021	Aug '20 Aug 31, 2020	2015 - 2019
Selling, General & Admin	1.42	1.37	2.68	2.92	2.25	2.6	Upgrade
Research & Development	0.52	0.65	1.1	2.29	4.8	2.68	Upgrade
Operating Expenses	2.16	2.31	5.03	5.74	7.88	8.45	Upgrade
Operating Income	-2.16	-2.31	-5.03	-5.74	-7.88	-8.45	Upgrade
Interest & Investment Income	0	0	0	0	0.01	0.04	Upgrade
Other Non Operating Income (Expenses)	-0.12	-0.11	-0.21	-0.23	-0.17	-0.21	Upgrade
EBT Excluding Unusual Items	-2.27	-2.41	-5.24	-5.97	-8.04	-8.63	Upgrade
Gain (Loss) on Sale of Assets	1.66	1.66	-	-	-	-0	Upgrade
Asset Writedown	-	-	-1.54	-0.04	-	-0.05	Upgrade
Other Unusual Items	0.25	0.25	-	-0.05	0.31	0.14	Upgrade
Pretax Income	-0.36	-0.5	-6.78	-6.05	-7.73	-8.54	Upgrade
Net Income	-0.36	-0.5	-6.78	-6.05	-7.73	-8.54	Upgrade
Net Income to Common	-0.36	-0.5	-6.78	-6.05	-7.73	-8.54	Upgrade
Shares Outstanding (Basic)	23	20	15	7	6	4	Upgrade
Shares Outstanding (Diluted)	23	20	15	7	6	4	Upgrade
Shares Change (YoY)	37.20%	32.35%	117.87%	11.59%	76.84%	97.19%	Upgrade
EPS (Basic)	-0.02	-0.03	-0.45	-0.87	-1.24	-2.42	Upgrade
EPS (Diluted)	-0.02	-0.03	-0.45	-0.87	-1.24	-2.42	Upgrade
Free Cash Flow	-2.9	-2.71	-2.55	-2.91	-7.82	-6.61	Upgrade
Free Cash Flow Per Share	-0.13	-0.14	-0.17	-0.42	-1.26	-1.88	Upgrade
EBITDA	-2.13	-2.28	-4.98	-5.71	-	-8.42	Upgrade
D&A For EBITDA	0.02	0.03	0.05	0.03	-	0.03	Upgrade
EBIT	-2.16	-2.31	-5.03	-5.74	-7.88	-8.45	Upgrade

Updated Jan 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.